Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Goodwin Procter LLP. (11/2/17). "Press Release: Ocera Therapeutics Acquired by Mallinckrodt for $42 Million".

Organisations Organisation Goodwin Procter LLP
  Group Goodwin Procter (Goowin Law) (Group)
  Organisation 2 Ocera Therapeutics Inc. (Nasdaq: OCRX)
  Group Mallinckrodt (Group)
Products Product legal services
  Product 2 OCR-002 (Ocera Therapeutics)
Index term Index term Ocera Therapeutics–Mallinckrodt: investment, 201711– cash tender offer for Ocera Therapeutics Inc by sub of Mallinckrodt plc
Persons Person Lang, Daniel A. (Goodwin Procter 201711 Partner)
  Person 2 Bloom, Mitchell S. (Goodwin Procter 201711 Partner)

The Life Sciences team represented Ocera Therapeutics, Inc. (NASDAQ:OCRX) in its agreement to be acquired by Mallinckrodt plc (NYSE:MNK). A subsidiary of Mallinckrodt will commence a cash tender offer to purchase all of the outstanding shares of Ocera Therapeutics common stock for $1.52 per share (approximately $42 million), plus one contingent value right to receive one or more payments in cash of up to $2.58 per share (up to approximately $75 million) based on the successful completion of certain development and sales milestones. The transaction is expected to close in the fourth quarter of 2017, subject to customary closing conditions.

Ocera’s developmental product OCR-002, an ammonia scavenger, is being studied for treatment of hepatic encephalopathy (HE), a neuropsychiatric syndrome associated with hyperammonemia, a complication of acute or chronic liver disease. If approved, OCR-002 is expected to become the first intravenous pharmacologic option indicated for treatment of acute HE in the U.S. Roughly 200,000 U.S. hospitalizations result from acute HE each year and approximately 1.5 to 2 million patients are at risk of recurrent HE.

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 has been granted Orphan Drug designation and fast track status by the U.S. Food and Drug Administration for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.

The Goodwin team was led by partner Daniel Lang, and included partners Mitchell Bloom, Karen Spindler, Andrew Goodman and Sarah Bock, and associates Claudia Torres and John Casnocha.

For additional details on the acquisition, please read the press release.

Related Professionals

Daniel A. Lang
Mitchell S. Bloom
Karen A. Spindler
Andrew H. Goodman
Sarah M. Bock
Claudia F. Torres
John G. Casnocha

Record changed: 2021-04-26


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Goodwin Procter (Goowin Law) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top